Format

Send to

Choose Destination
Hematol Oncol Clin North Am. 2008 Dec;22(6):1267-78, x. doi: 10.1016/j.hoc.2008.08.012.

Update on the management and therapeutic monitoring of advanced nasopharyngeal cancer.

Author information

1
Department of Clinical Oncology, Prince of Wales Hospital, Shatin, New Territories, Hong Kong SAR.

Abstract

Despite being potentially curable at an early stage, more than 50% of patients who have nasopharyngeal carcinoma present with advanced locoregional disease, which results in a poor prognosis. This article discusses key advancements in the management of nasopharyngeal cancer, including the incorporation of concurrent chemoradiotherapy, new radiotherapy delivery techniques in the form of conformal and intensity-modulated radiotherapy, and salvage options for locoregional recurrence. New cytotoxic and targeted therapies that have resulted in improved survival in the metastatic setting are also described. The use of Epstein-Barr virus DNA for the prognostication and monitoring of nasopharyngeal cancer and the role of new diagnostic imaging techniques are also discussed.

PMID:
19010273
DOI:
10.1016/j.hoc.2008.08.012
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center